Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Mar 14, 2023 (4 years ago)

Dabigatran Etexilate 150mg Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.

Cause type: Nitrosamine impurity

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls. All nitrosamine impurity recalls.

What was recalled

Dabigatran Etexilate 150mg Capsules, 150 mg, Rx Only, 60 Capsules per bottle, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054, NDC 67877-475-60.

Affected NDC 67877-0475-60

Compare with the code on your package — it is the most precise check available.

Drug: Dabigatran

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Dabigatran Etexilate
NDC 67877-0475
MESYLATE 150 mg/1 Capsule, Coated Pellets
Oral
Ascend Laboratories, LLC Rx
Recalling firm
Ascend Laboratories, LLC
NDC code
67877-475-60
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0534-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Dabigatran recalls

See all
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7253-04 D-0739-2026
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7253-68 D-0738-2026
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7255-68 D-0737-2026
Class III · Low risk

Dabigatran etexilate Capsules

Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7255-10 D-0736-2026
Class III · Low risk

Dabigatran etexilate Capsules

Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7254-68 D-0735-2026

Other recalls by Ascend Laboratories, LLC

All 2023 recalls
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7253-04 D-0739-2026
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7253-68 D-0738-2026
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7255-68 D-0737-2026